Who
Kristin Yarema
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, ImageneBio; President and CEO, Poseida Therapeutics; Chief Commercial Officer, Atara Biotherapeutics.
In numbers
- Trades disclosed
- 37
- Buys
- 2
- Sells
- 1
- Bought
- $500K
- Sold
- $11K
- Companies
- 3
- Companies where not an officer
- 0
- First trade
- 18 Feb 2020
- Last trade
- 14 Aug 2026
- Last filed
- 17 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 14 Aug 2026filed 17 Aug 2026 | IMA ImageneBioBiotechnology | SEC FORM 4 Code A | —254,800 at $0.00 | filing |
| 14 Aug 2026filed 17 Aug 2026 | IMA ImageneBiooption or derivative · Biotechnology | SEC FORM 4 Code A | —137,200 at $0.00 | filing |
| 14 Aug 2026filed 17 Aug 2026 | IMA ImageneBiooption or derivative · Biotechnology | SEC FORM 4 Code A | —250,000 at $0.00 | filing |
| 14 Aug 2026filed 17 Aug 2026 | IMA ImageneBiooption or derivative · Biotechnology | SEC FORM 4 Code A | —137,200 at $0.00 | filing |
| 14 Aug 2026filed 17 Aug 2026 | IMA ImageneBiooption or derivative · Biotechnology | SEC FORM 4 Code A | —250,000 at $0.00 | filing |
| 14 Aug 2026filed 17 Aug 2026 | IMA ImageneBioBiotechnology | SEC FORM 4 Code A | —254,800 at $0.00 | filing |
| 25 Jul 2026filed 28 Jul 2026 | IMA ImageneBioBiotechnology | SEC FORM 4 Code M | —38,376 at $0.00 | filing |
| 25 Jul 2026filed 28 Jul 2026 | IMA ImageneBioBiotechnology | SEC FORM 4 Code J | —115,129 at $0.00 | filing |
| 25 Jul 2026filed 28 Jul 2026 | IMA ImageneBiooption or derivative · Biotechnology | SEC FORM 4 Code M | —38,376 at $0.00 | filing |
| 25 Jul 2026filed 28 Jul 2026 | IMA ImageneBiooption or derivative · Biotechnology | SEC FORM 4 Code M | —38,376 at $0.00 | filing |
| 25 Jul 2026filed 28 Jul 2026 | IMA ImageneBiooption or derivative · Biotechnology | SEC FORM 4 Code J | —115,129 at $0.00 | filing |
| 25 Jul 2026filed 28 Jul 2026 | IMA ImageneBiooption or derivative · Biotechnology | SEC FORM 4 Code J | —115,129 at $0.00 | filing |
| 25 Jul 2026filed 28 Jul 2026 | IMA ImageneBioBiotechnology | SEC FORM 4 Code M | —38,376 at $0.00 | filing |
| 25 Jul 2026filed 28 Jul 2026 | IMA ImageneBioBiotechnology | SEC FORM 4 Code J | —115,129 at $0.00 | filing |
| 16 Mar 2026filed 18 Mar 2026 | IMA ImageneBioBiotechnology | SEC FORM 4 Code A | —85,400 at $0.00 | filing |
| 16 Mar 2026filed 18 Mar 2026 | IMA ImageneBiooption or derivative · Biotechnology | SEC FORM 4 Code A | —128,100 at $0.00 | filing |
| 16 Mar 2026filed 18 Mar 2026 | IMA ImageneBiooption or derivative · Biotechnology | SEC FORM 4 Code A | —128,100 at $0.00 | filing |
| 16 Mar 2026filed 18 Mar 2026 | IMA ImageneBioBiotechnology | SEC FORM 4 Code A | —85,400 at $0.00 | filing |
| 28 Jul 2025filed 30 Jul 2025 | IMA ImageneBiooption or derivative · Biotechnology | SEC FORM 4 Code A | —460,515 at $0.00 | filing |
| 28 Jul 2025filed 30 Jul 2025 | IMA ImageneBiooption or derivative · Biotechnology | SEC FORM 4 Code A | —153,505 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.